816 related articles for article (PubMed ID: 15228642)
1. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
6. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
8. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
11. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
Ritchie CW; Ames D; Clayton T; Lai R
Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
13. [Medical treatment of Alzheimer's disease].
Johannsen P
Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
15. Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
Prescrire Int; 2003 Dec; 12(68):230-1. PubMed ID: 14986699
[TBL] [Abstract][Full Text] [Related]
16. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
17. Acetylcholinesterase inhibition in Alzheimer's Disease.
Ibach B; Haen E
Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
[TBL] [Abstract][Full Text] [Related]
18. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Kurz A; Van Baelen B
Dement Geriatr Cogn Disord; 2004; 18(2):217-26. PubMed ID: 15237280
[TBL] [Abstract][Full Text] [Related]
19. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
20. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
